Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 9.80B P/E - EPS this Y 126.70% Ern Qtrly Grth -
Income 47.3M Forward P/E 45.73 EPS next Y 605.20% 50D Avg Chg -11.00%
Sales 1.5B PEG 0.84 EPS past 5Y - 200D Avg Chg -15.00%
Dividend N/A Price/Book 13.23 EPS next 5Y 96.00% 52W High Chg -34.00%
Recommedations 1.70 Quick Ratio 2.69 Shares Outstanding 95.37M 52W Low Chg 9.00%
Insider Own 4.38% ROA 0.73% Shares Float 91M Beta 0.81
Inst Own 93.75% ROE 5.20% Shares Shorted/Prior 6.15M/6.73M Price 105.19
Gross Margin 37.13% Profit Margin 3.14% Avg. Volume 1,427,025 Target Price 188.73
Oper. Margin -0.19% Earnings Date Oct 30 Volume 888,300 Change -2.18%
About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics, Inc. News
11/15/24 Sarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy Now
11/13/24 Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem
11/12/24 Sarepta recent weakness brings buying opportunity, says JPMorgan
11/08/24 Sarepta price target lowered to $193 from $200 at Baird
11/07/24 SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
11/07/24 Sarepta scraps a Duchenne drug as gene therapy sales rise
11/07/24 Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript
11/07/24 Sarepta Therapeutics Inc (SRPT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
11/06/24 Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
11/06/24 Sarepta Therapeutics: Q3 Earnings Snapshot
11/06/24 Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments
10/31/24 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/27/24 Sarepta Therapeutics, Inc. (SRPT): An Unstoppable Stock That Could Make You Richer
10/23/24 Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
10/22/24 Exploring High Growth Tech Stocks In United States October 2024
10/18/24 Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
10/17/24 2 High-Flying Growth Stocks With Massive Upside Potential
10/16/24 Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Biotech Stock According to Hedge Funds?
10/03/24 Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
09/30/24 Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts?
SRPT Chatroom

User Image flash9875 Posted - 6 hours ago

$SRPT no screaming in the closet. Get out now before your wife finds out.

User Image patatechaude Posted - 7 hours ago

$CAPR I see RFKjr as an asset. Cells coming from a dead person’s healthy hearth given to increase heart capacity of DMD patients or any other cardiomyopathy suffering person is exactly his thing. Vaccines without adjuvants is exactly his motto. I’m not a big fan but I can see Capricor becoming huge under him. On the other hand, $SRPT asking for million$ and not producing studies to back their stuff is exactly what he wants out. $CAPR will thrive with or without RFKjr. $XBI

User Image Kanter1 Posted - 7 hours ago

$SRPT do these guys not get it Noone believes a word they say Reputations deservedly ruined And yet they keep it up Obviously not one of these analyst know anything about how stocks trade

User Image biomaster22 Posted - 7 hours ago

$SRPT flash learn from history they have been doing this for years. look at the 3 yr chart. you should be buying. kanter is the same crybaby that was posting on yahoo he owns it @ 127 and is underwater. I bet they announce suprise update at jan conference

User Image flash9875 Posted - 8 hours ago

$SRPT do they come up with these absurd price targets so they can try to run the price up so they can unload for their clients ? Ok..let’s see if another one comes out with A 250:price target today … this is all really sad. You can’t make diamonds out of coal…

User Image free2dream Posted - 9 hours ago

$SRPT rare disease company with pricing power ! $3B 2025 revenue, Sarepta is way undervalued here. Nothing JFK will do , he won’t fix these kids with healthy diet , only idiot would think so

User Image Kanter1 Posted - 9 hours ago

$SRPT fucking bullshit analyst continue to fuck retail investors over with these 200 price targets sarepta will never see Just read the previous post Same price in 2017 while most stocks tripled at least Anyone that defends this piece of shit is an idiot

User Image Tumble51 Posted - 11 hours ago

$SRPT How’s Doug these days ? Still collecting big money ? With the same story in 2017 he came with ?? Lol….this was at $104 in October of 2017 …!! What a winner huh ??? MSFT was $92 then !

User Image rogertrades Posted - 15 hours ago

$SRPT lmao

User Image GetThePapersGetThePapers Posted - 1 day ago

$SRPT this is truly the biggest pos ive ever owned, but i know one day this will explode so i will just sit here with patience

User Image CDMO Posted - 1 day ago

$SRPT added

User Image Quantumup Posted - 1 day ago

BofA reiterated $SRPT Buy/$210, says Competitor $RGNX DMD gene therapy data still early; Hard to draw conclusion to Elevidys based on small N—Based on KOL✅s doesn't think MDs would hold back on Tx'g given pts get worse over⏲️—est $4.3B in peak Elevidys sales; 60% penetration—📝SRPT also looking to expand to younger pts: $ewtx

User Image Shah_BaBa Posted - 1 day ago

$SRPT why the price is keep falling despite the approval, good earnings and much better guidance for the next year. What are the worries or any concerns of investors for keep selling and selling

User Image penelope6 Posted - 1 day ago

$SRPT next support 96 they will dumb it down farther

User Image Kanter1 Posted - 1 day ago

$SRPT wow 100 not holding today And no comment from 200 dollar analysts or Ingram

User Image flash9875 Posted - 1 day ago

$SRPT One last window to recoup your dollars…sell SRpt and buy capr

User Image flash9875 Posted - 1 day ago

$SRPT continuation …mid 90s this week….the fat is dripping out

User Image flash9875 Posted - 1 day ago

$SRPT Will this stock bleed out this week ?

User Image rogertrades Posted - 1 day ago

$SRPT 52 week low test coming.

User Image penelope6 Posted - 1 day ago

$SRPT this time its death by 1000 cuts not like the 88 pt drop in one night not long ago.

User Image biomaster22 Posted - 2 days ago

$SRPT Flash why don't you go back the the train you missed on CAPR since you know nothing about FDA and a approval will never be recinded there is no harful effects of Elevidys on patients !

User Image flash9875 Posted - 3 days ago

$SRPT What will happen when the fda withdraws approval ?

User Image BrendanShaffer Posted - 3 days ago

😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $SRPT $CTLT

User Image GetThePapersGetThePapers Posted - 4 days ago

@Marconzi $srpt.. go look at their earnings on nov 6th.. double beat.. this will recover when the smoke blows over

User Image free2dream Posted - 4 days ago

$XBI RFK jr has ZERO qualifications to run HHS nor FDA. You morons have to wake the fuck up ! $LABU $MRNA $SRPT $CLDX

User Image Markus_Montag Posted - 4 days ago

$SRPT Strange week

User Image Cutlass Posted - 4 days ago

$SRPT And filled ✔

User Image ndgt10 Posted - 4 days ago

$SRPT Gap filled

User Image biomaster22 Posted - 4 days ago

$SRPT excellent work Doug approval, what approval joke !

User Image ndgt10 Posted - 4 days ago

$SRPT Wow. This thing is cooked

Analyst Ratings
Cantor Fitzgerald Neutral Sep 20, 24
RBC Capital Outperform Sep 19, 24
RBC Capital Outperform Sep 6, 24
RBC Capital Outperform Aug 15, 24
RBC Capital Outperform Aug 8, 24
Citigroup Neutral Aug 8, 24
Cantor Fitzgerald Neutral Aug 8, 24
Evercore ISI Group Outperform Aug 8, 24
Barclays Overweight Aug 8, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Barry Richard Director Director Nov 03 Buy 78.81 50,000 3,940,500 140,000 11/06/23
INGRAM DOUGLAS S President & CEO President & CEO Nov 03 Buy 79.97 25,225 2,017,243 390,307 11/06/23
BEHRENS M KATHLEEN Director Director Nov 03 Option 29.03 15,000 435,450 174,993 11/06/23
Chambers Michael Andrew Director Director Aug 14 Buy 109.54 9,979 1,093,100 246,996 08/15/23
Chambers Michael Andrew Director Director Aug 11 Buy 108.05 23,686 2,559,272 237,017 08/14/23
Chambers Michael Andrew Director Director Aug 10 Buy 105.61 34,867 3,682,304 213,331 08/11/23
Wigzell Hans Lennart Rudolf Director Director Aug 04 Sell 106.72 15,000 1,600,800 20,994 08/08/23
Wigzell Hans Lennart Rudolf Director Director Aug 04 Option 29.03 15,000 435,450 35,994 08/08/23
BEHRENS M KATHLEEN Director Director Dec 19 Option 34.92 20,000 698,400 158,470 12/21/22
Mayo Stephen Director Director Nov 17 Sell 109.92 858 94,311 6,387 11/21/22
Chambers Michael Andrew Director Director Sep 14 Buy 104.57 57,100 5,970,947 108,178 09/15/22
Chambers Michael Andrew Director Director Aug 19 Buy 108.5 46,170 5,009,445 51,078 08/22/22
BEHRENS M KATHLEEN Director Director Mar 10 Option 42.3 5,000 211,500 135,517 03/10/21
BEHRENS M KATHLEEN Director Director Mar 10 Sell 85.76 5,000 428,800 130,517 03/10/21
Wigzell Hans Lennart Rudolf Director Director Mar 10 Option 34.92 10,000 349,200 26,518 03/10/21
Wigzell Hans Lennart Rudolf Director Director Mar 10 Sell 83.51 10,000 835,100 16,518 03/10/21
Bratica Joseph Principal Financial.. Principal Financial Officer Dec 10 Option 29.6 1,125 33,300 9,265 12/10/20
Bratica Joseph Principal Financial.. Principal Financial Officer Dec 10 Sell 160 1,125 180,000 8,140 12/10/20